Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
VBIO
VALION BIO, INC.
NASDAQ
$2.12
▼ DOWN 4.93% (-0.11)

KEY STATISTICS

Market Cap$8.78 M
52w High$78.75
52w Low$2.05
Dividend Yield—
Frequency—
P/E-0.95
Volume56.88K
Shares Out.4.14M

COMPANY

LEADERSHIP

Michael R. Cavanaugh
CHIEF EXECUTIVE
Michael R. Cavanaugh

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 11, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
52

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.$460.00K
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2026-08-31Reverse1:25
2016-07-20Reverse1:10

PRICE

$2.12 ▼ DOWN 4.93% (−$0.11)
OVERLAYS
$2.17$2.25$2.339:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.12

About Valion Bio, Inc.

https://valionbio.com ↗

Valion Bio, Inc., a late-stage biopharmaceutical company based in San Antonio, Texas, develops Entolimod for radiation, neutropenia, and immunosenescence, offers CDMO services, and was formerly Tivic Health Systems.

INDUSTRY

Biotechnology

A PRODUCT VALION BIO, INC. IS KNOWN FOR

Entolimod
Entolimod

Entolimod, Valion Bio's lead TLR5 agonist, is a clinical-stage drug developed as a medical countermeasure for Acute Radiation Syndrome under the FDA's Animal Rule and is also being explored for oncology supportive care.

COMPETITORS

COMPETITOR
AMGN COMPARE
INDP COMPARE
ON ONTX COMPARE
PLUR COMPARE
SNGX COMPARE

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

★
DIRECTOR:
Malbin Jared David
— · —
2026-08-27
★
DIRECTOR:
Jensen Thomas
— · —
2026-08-27
★
OFFICER: CHIEF FINANCIAL OFFICER
Wolf Lisa G
Purchase · 92 shares
2026-06-18
★
OFFICER: CHIEF FINANCIAL OFFICER
Wolf Lisa G
Sale · 92 shares
2026-06-18